Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 25, Issue 7, 2015, Pages 1616-1620

  Austin, Rupert P ^a   Bennion, Colin ^a   Bonnert, Roger V ^a   Cheema, Lal ^a   Cook, Anthony R ^a   Cox, Rhona J ^a,b   Ebden, Mark R ^a   Gaw, Alasdair ^a   Grime, Ken ^a,b   Meghani, Premji ^a   Nicholls, David ^a   Phillips, Caroline ^a   Smith, Neal ^a   Steele, John ^a,b   Stonehouse, Jeffrey P ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Chemokine antagonism; CXCR2; Inflammatory disease; Solubility

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; SULFONAMIDE; AMIDE; PYRIMIDINE; PYRIMIDINE DERIVATIVE;

ARTICLE; BINDING AFFINITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PLASMA PROTEIN BINDING; STRUCTURE ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; CHEMISTRY; CONFORMATION; DOSE RESPONSE; DRUG DEVELOPMENT; RAT; SOLUBILITY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

AMIDES; ANIMALS; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HUMANS; MOLECULAR CONFORMATION; PYRIMIDINES; RATS; RECEPTORS, INTERLEUKIN-8B; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84925059188     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2015.01.067     Document Type: Article

References (26)

1. W.E. Holmes, J. Lee, W.J. Kuang, G.C. Rice, and W.I. Wood Science 253 1991 1278
2. P.M. Murphy, and H.L. Tiffany Science 253 1991 1280
3. A. Matsukawa, T. Yoshimura, K. Fujiwara, T. Maeda, S. Ohkawara, and M. Yoshinaga Lab. Invest. 79 1999 591
4. D.W.P. Hay, and H.M. Sarau Curr. Opin. Pharmacol. 1 2001 242
5. C. Bizzarri, M. Allegretti, R. Di Bitondo, M.N. Cervellera, F. Colotta, and R. Bertini Curr. Med. Chem. Anti-Inflamm. Anti-Allergy Agents 2 2003 67
6. G. Cacalano, J. Lee, K. Kikly, A.M. Ryan, S. Pitts-Meek, B. Hultgren, W.I. Wood, and M.W. Moore Science 265 1994 682
7. For examples see (a) J.J. Li, K.G. Carson, B.K. Trivedi, W.S. Yue, Q. Ye, R.A. Glynn, S.R. Miller, D.T. Connor, B.D. Roth, J.R. Luly, J.E. Low, D.J. Heilig, W. Yang, S. Qin, and S. Hunt Bioorg. Med. Chem. 11 2003 3777
8. K.L. Widdowson, J.D. Elliott, D.F. Veber, H. Nie, M.C. Rutledge, B.W. McCleland, J.-N. Xiang, A.J. Jurewicz, R.P. Hertzberg, J.J. Foley, D.E. Griswold, L. Martin, J.M. Lee, J.R. White, and H.M. Sarau J. Med. Chem. 47 2004 1319
9. M.P. Dwyer, Y. Yu, J. Chao, C. Aki, J. Chao, P. Biju, V. Girijavallabhan, D. Rindgen, R. Bond, R. Mayer-Ezel, J. Jakway, R.W. Hipkin, J. Fossetta, W. Gonsiorek, H. Bian, X. Fan, C. Terminelli, J. Fine, D. Lundell, J.R. Merritt, L.L. Rokosz, B. Kaiser, G. Li, W. Wang, T. Stauffer, L. Ozgur, J. Baldwin, and A.G. Taveras J. Med. Chem. 49 2006 7603
10. M.P. Dwyer, and Y. Yu Expert Opin. Ther. Patents 24 2014 519 and references therein
11. P. Nair, M. Gaga, E. Zervas, K. Alagha, F.E. Hargreave, P.M. O'Byrne, P. Stryszak, L. Gann, J. Sadeh, and P. Chanez Clin. Exp. Allergy 42 2012 1097
12. R.B. Moss, S.J. Mistry, M.W. Konstan, J.M. Pilewski, E. Kerem, R. Tal-Singer, and A.L. Lazaar J. Cyst. Fibros. 12 2013 241
13. A. Baxter, A. Cooper, E. Kinchin, K. Moakes, J. Unitt, and A. Wallace Bioorg. Med. Chem. Lett. 16 2006 960
14. F. Hunt, C. Austin, R. Austin, R. Bonnert, P. Cage, J. Christie, M. Christie, C. Dixon, S. Hill, R. Jewell, I. Martin, D. Robinson, and P. Willis Bioorg. Med. Chem. Lett. 17 2007 2731
15. I. Walters, C. Austin, R. Austin, R. Bonnert, P. Cage, M. Christie, M. Ebden, S. Gardiner, C. Grahames, S. Hill, F. Hunt, R. Jewell, S. Lewis, I. Martin, D. Nicholls, and D. Robinson Bioorg. Med. Chem. Lett. 18 2008 798
16. For examples of improving solubility by disruption of crystal packing see: (a) M.J. Fray, D.J. Bull, C.L. Carr, E.C.L. Gautier, C.E. Mowbray, and A. Stobie J. Med. Chem. 44 2001 1951
17. S.S. Nikam, J.J. Cordon, D.F. Ortwine, T.H. Heimbach, A.C. Blackburn, M.G. Vartanian, C.B. Nelson, R.D. Schwartz, P.A. Boxer, and M.F. Rafferty J. Med. Chem. 42 1999 2266
18. Ebden, M. R.; Meghani, P.; Bennion, C.; Cook, A. R.; Bonnert, R. V. WO2004/011443, 2004; Chem. Abstr. 2004, 140, 163884.
19. L. Alcaraz, C. Bennion, J. Morris, P. Meghani, and S. Thom Org. Lett. 6 2004 2705
20. Log D was measured using a shake flask technique followed by HPLC analysis with quantitative MS.
21. D.J. Nicholls, N.P. Tomkinson, K.E. Wiley, A. Brammall, L. Bowers, C. Grahames, A. Gaw, P. Meghani, P. Shelton, T.J. Wright, and P.R. Mallinder Mol. Pharmacol. 74 2008 1193
22. K. Salchow, M.E. Bond, S.C. Evans, N.J. Press, S.J. Charlton, P.A. Hunt, and M.E. Bradley Br. J. Pharmacol. 159 2010 1429
23. int was determined according to the method described in M.G. Soars, K. Grime, J.L. Sproston, P.J.H. Webborn, and R.J. Riley Drug Metab. Dispos. 35 2007 859
24. app was determined according to the method described in G. Camenisch, J. Alsenz, H. van de Waterbeemd, and G. Folkers Eur. J. Pharm. Sci. 6 1998 313
25. All animal studies were carried out under licences issued under the Animals (Scientific Procedures) Act 1986 following local ethical committee review.
26. All compounds for IV dosing were formulated in DMA/PEG/saline. All compounds for oral dosing were formulated in Tween/CMC except for 47, which was formulated in DMA/PEG/saline.